000			02256 a2200601 4500
005			20250516013134.0
264		0	_c20110224
008			201102s 0 0 eng d
022			_a1096-0333
024	7		_a10.1016/j.taap.2010.11.007 _2doi
040			_aNLM _beng _cNLM
100	1		_aFang, Liang
245	0	0	_aFOXO3a reactivation mediates the synergistic cytotoxic effects of rapamycin and cisplatin in oral squamous cell carcinoma cells. _h[electronic resource]
260			_bToxicology and applied pharmacology _cFeb 2011
300			_a8-15 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAnimals
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xpharmacology
650	0	4	_aApoptosis _xdrug effects
650	0	4	_aApoptosis Regulatory Proteins _xmetabolism
650	0	4	_aBcl-2-Like Protein 11
650	0	4	_aCarcinoma, Squamous Cell _xdrug therapy
650	0	4	_aCell Line, Tumor
650	0	4	_aCell Proliferation _xdrug effects
650	0	4	_aCisplatin _xpharmacology
650	0	4	_aCyclin-Dependent Kinase Inhibitor p27 _xmetabolism
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aDrug Synergism
650	0	4	_aForkhead Box Protein O3
650	0	4	_aForkhead Transcription Factors _xgenetics
650	0	4	_aHumans
650	0	4	_aMale
650	0	4	_aMembrane Proteins _xmetabolism
650	0	4	_aMice
650	0	4	_aMice, Inbred BALB C
650	0	4	_aMice, Nude
650	0	4	_aMolecular Targeted Therapy
650	0	4	_aPhosphorylation
650	0	4	_aProtein Kinase Inhibitors _xpharmacology
650	0	4	_aProto-Oncogene Proteins _xmetabolism
650	0	4	_aProto-Oncogene Proteins c-akt _xantagonists & inhibitors
650	0	4	_aS-Phase Kinase-Associated Proteins _xmetabolism
650	0	4	_aSirolimus _xpharmacology
650	0	4	_aTime Factors
650	0	4	_aTongue Neoplasms _xdrug therapy
650	0	4	_aTumor Burden _xdrug effects
650	0	4	_aXenograft Model Antitumor Assays
700	1		_aWang, Huiming
700	1		_aZhou, Lin
700	1		_aYu, Da
773	0		_tToxicology and applied pharmacology _gvol. 251 _gno. 1 _gp. 8-15
856	4	0	_uhttps://doi.org/10.1016/j.taap.2010.11.007 _zAvailable from publisher's website
999			_c20388968 _d20388968